Abstract

To investigate the feasibility of combining coronary computed tomography (CT) angiography (CCTA) and CTA to evaluate access vessels for transcatheter aortic valve replacement (TAVR) patients in free-breathing and with single contrast medium injection using a 16-cm-wide detector CT. One hundred and twenty-one consecutive patients (73.33 ± 6.43 years) referred for TAVR underwent a serious CT scans in free-breathing after one contrast injection: ECG-triggered one-heartbeat axial CCTA, followed by non-ECG-gated neck, thoracic, and abdominal CTA. Patient weight-dependent contrast dose volume at 1.0 mL/kg was used. CT attenuation values of the coronary, neck, aortic, iliac, and femoral arteries were measured and their image quality was evaluated with a 4-point score method. Stenosis (≥50%) in CCTA was evaluated using invasive coronary angiography result as a reference standard. Radiation and contrast doses were assessed. The total dose-length-product for the entire examination was 411.4 ± 91.2 mGy.cm, and the total contrast dose was 57.3 ± 9.9 mL. There were adequate attenuations (>400 HU) in all arteries, and the peripheral access vessels and aortic annulus were evaluable in all patients. In neck CTA, 5 patients had vascular tortuosity, 6 patients had aberrant arteries and there were 212 plaques and 13 severe stenoses among the patients. In CCTA, on the per-segment, per-vessel, and per-patient analysis, CCTA showed a sensitivity and negative predictive value of (95% and 99%), (95% and 99%), and (96% and 98%), respectively, for the entire patient cohort, and (92% and 98%), (92% and 98%), and (88% and 93%), respectively, for patients with atrial fibrillation or heart rate higher than 75 beats. It is feasible to perform a combined CCTA and CTA for evaluating access vessels for TAVR patients in free-breathing with single contrast injection. This approach generates acceptable image quality for all vessels and a high negative predictive value in excluding coronary artery disease with relatively low radiation and contrast doses.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.